Cargando…
Personalising laboratory medicine in the ‘real world’: Assessing clinical utility, by clinical indication, of serum total B(12) and Active-B(12)® (holotranscobalamin) in the diagnosis of vitamin B(12) deficiency
BACKGROUND: Assessing the pre- and post-test probability of disease in the context of routine health care is challenging. We wished to study how test performance parameters relating to clinical utility vary by clinical indication in a ‘real-world’ setting. METHODS: The diagnostic accuracy of serum t...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8458683/ https://www.ncbi.nlm.nih.gov/pubmed/33715445 http://dx.doi.org/10.1177/00045632211003605 |
_version_ | 1784571348061782016 |
---|---|
author | Murphy, Michael J Brandie, Fiona Ebare, Mildred Harrison, Michelle Dow, Ellie Bartlett, William A Craig, David |
author_facet | Murphy, Michael J Brandie, Fiona Ebare, Mildred Harrison, Michelle Dow, Ellie Bartlett, William A Craig, David |
author_sort | Murphy, Michael J |
collection | PubMed |
description | BACKGROUND: Assessing the pre- and post-test probability of disease in the context of routine health care is challenging. We wished to study how test performance parameters relating to clinical utility vary by clinical indication in a ‘real-world’ setting. METHODS: The diagnostic accuracy of serum total B(12) and Active-B(12)® (holotranscobalamin) was evaluated in a primary care population, using serum methylmalonic acid as the reference standard. We used electronic requesting to establish the clinical indication for each request. Routine requests from primary care for serum total B(12) were included if creatinine was also measured and estimated glomerular filtration rate was at least 60 mL/min/1.73 m(2). RESULTS: Clinical indications included peripheral neuropathy (n = 168), anaemia (n = 168), cognitive decline (n = 125), suspected dietary deficiency (n = 76), other (n = 362). For peripheral neuropathy, the area under the receiver operator curve ± 95% confidence interval (AUC ± CI) was 0.63 (0.54–0.71) (P = 0.002) for total B(12) and 0.68 (0.60–0.77) (P < 0.0001) for Active-B(12)®. For anaemia, AUC ± CI was 0.56 (0.47–0.66) (P = 0.10) for total B(12) and 0.69 (0.59–0.78) (P < 0.0001) for Active-B(12)®. For cognitive decline, AUC ± CI was 0.54 (0.43–0.65) (P = 0.26) for total B(12) and 0.69 (0.58–0.80) (P = 0.0002) for Active-B(12)®. The pre–post-test change in probability of disease varied by clinical indication. CONCLUSION: Combining diagnostic accuracy studies and electronic testing in a ‘real-world’ setting allows clinical utility to be assessed by clinical indication. Wider application of this would permit more personalised laboratory medicine. In this study, diagnostic performance of total B(12) and Active-B(12)® varied across all indications. Active-B(12)® provided better discrimination, but this may have reflected the cut-offs used. |
format | Online Article Text |
id | pubmed-8458683 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-84586832021-09-24 Personalising laboratory medicine in the ‘real world’: Assessing clinical utility, by clinical indication, of serum total B(12) and Active-B(12)® (holotranscobalamin) in the diagnosis of vitamin B(12) deficiency Murphy, Michael J Brandie, Fiona Ebare, Mildred Harrison, Michelle Dow, Ellie Bartlett, William A Craig, David Ann Clin Biochem Research Articles BACKGROUND: Assessing the pre- and post-test probability of disease in the context of routine health care is challenging. We wished to study how test performance parameters relating to clinical utility vary by clinical indication in a ‘real-world’ setting. METHODS: The diagnostic accuracy of serum total B(12) and Active-B(12)® (holotranscobalamin) was evaluated in a primary care population, using serum methylmalonic acid as the reference standard. We used electronic requesting to establish the clinical indication for each request. Routine requests from primary care for serum total B(12) were included if creatinine was also measured and estimated glomerular filtration rate was at least 60 mL/min/1.73 m(2). RESULTS: Clinical indications included peripheral neuropathy (n = 168), anaemia (n = 168), cognitive decline (n = 125), suspected dietary deficiency (n = 76), other (n = 362). For peripheral neuropathy, the area under the receiver operator curve ± 95% confidence interval (AUC ± CI) was 0.63 (0.54–0.71) (P = 0.002) for total B(12) and 0.68 (0.60–0.77) (P < 0.0001) for Active-B(12)®. For anaemia, AUC ± CI was 0.56 (0.47–0.66) (P = 0.10) for total B(12) and 0.69 (0.59–0.78) (P < 0.0001) for Active-B(12)®. For cognitive decline, AUC ± CI was 0.54 (0.43–0.65) (P = 0.26) for total B(12) and 0.69 (0.58–0.80) (P = 0.0002) for Active-B(12)®. The pre–post-test change in probability of disease varied by clinical indication. CONCLUSION: Combining diagnostic accuracy studies and electronic testing in a ‘real-world’ setting allows clinical utility to be assessed by clinical indication. Wider application of this would permit more personalised laboratory medicine. In this study, diagnostic performance of total B(12) and Active-B(12)® varied across all indications. Active-B(12)® provided better discrimination, but this may have reflected the cut-offs used. SAGE Publications 2021-04-23 2021-09 /pmc/articles/PMC8458683/ /pubmed/33715445 http://dx.doi.org/10.1177/00045632211003605 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Research Articles Murphy, Michael J Brandie, Fiona Ebare, Mildred Harrison, Michelle Dow, Ellie Bartlett, William A Craig, David Personalising laboratory medicine in the ‘real world’: Assessing clinical utility, by clinical indication, of serum total B(12) and Active-B(12)® (holotranscobalamin) in the diagnosis of vitamin B(12) deficiency |
title | Personalising laboratory medicine in the ‘real world’: Assessing clinical utility, by clinical indication, of serum total B(12) and Active-B(12)® (holotranscobalamin) in the diagnosis of vitamin B(12) deficiency |
title_full | Personalising laboratory medicine in the ‘real world’: Assessing clinical utility, by clinical indication, of serum total B(12) and Active-B(12)® (holotranscobalamin) in the diagnosis of vitamin B(12) deficiency |
title_fullStr | Personalising laboratory medicine in the ‘real world’: Assessing clinical utility, by clinical indication, of serum total B(12) and Active-B(12)® (holotranscobalamin) in the diagnosis of vitamin B(12) deficiency |
title_full_unstemmed | Personalising laboratory medicine in the ‘real world’: Assessing clinical utility, by clinical indication, of serum total B(12) and Active-B(12)® (holotranscobalamin) in the diagnosis of vitamin B(12) deficiency |
title_short | Personalising laboratory medicine in the ‘real world’: Assessing clinical utility, by clinical indication, of serum total B(12) and Active-B(12)® (holotranscobalamin) in the diagnosis of vitamin B(12) deficiency |
title_sort | personalising laboratory medicine in the ‘real world’: assessing clinical utility, by clinical indication, of serum total b(12) and active-b(12)® (holotranscobalamin) in the diagnosis of vitamin b(12) deficiency |
topic | Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8458683/ https://www.ncbi.nlm.nih.gov/pubmed/33715445 http://dx.doi.org/10.1177/00045632211003605 |
work_keys_str_mv | AT murphymichaelj personalisinglaboratorymedicineintherealworldassessingclinicalutilitybyclinicalindicationofserumtotalb12andactiveb12holotranscobalamininthediagnosisofvitaminb12deficiency AT brandiefiona personalisinglaboratorymedicineintherealworldassessingclinicalutilitybyclinicalindicationofserumtotalb12andactiveb12holotranscobalamininthediagnosisofvitaminb12deficiency AT ebaremildred personalisinglaboratorymedicineintherealworldassessingclinicalutilitybyclinicalindicationofserumtotalb12andactiveb12holotranscobalamininthediagnosisofvitaminb12deficiency AT harrisonmichelle personalisinglaboratorymedicineintherealworldassessingclinicalutilitybyclinicalindicationofserumtotalb12andactiveb12holotranscobalamininthediagnosisofvitaminb12deficiency AT dowellie personalisinglaboratorymedicineintherealworldassessingclinicalutilitybyclinicalindicationofserumtotalb12andactiveb12holotranscobalamininthediagnosisofvitaminb12deficiency AT bartlettwilliama personalisinglaboratorymedicineintherealworldassessingclinicalutilitybyclinicalindicationofserumtotalb12andactiveb12holotranscobalamininthediagnosisofvitaminb12deficiency AT craigdavid personalisinglaboratorymedicineintherealworldassessingclinicalutilitybyclinicalindicationofserumtotalb12andactiveb12holotranscobalamininthediagnosisofvitaminb12deficiency |